AIM: To study the long-term visual and anatomical outcomes of antivascular endothelial growth factor (VEGF) monotherapy for the treatment of patients with retinal angiomatous proliferation (RAP). METHODS: Retrospective review of patients who were diagnosed as having AMD and RAP lesions, and who received anti-VEGF injections as the only mode of therapy. RESULTS: 20 eyes (15 patients; nine women, six men) with RAP lesions treated by anti-VEGF were encountered. The mean patient age was 85.8 years (SD+/-4.54). Nine eyes were treated with intravitreal ranibizumab alone, eight eyes were treated with bevacizumab alone, and three eyes received both drugs. At 1, 3 and 6 months' follow-up the median VA had improved from baseline (20/72) to 20/52 (range: 20/25 to 20/400), 20/45 (range 20/20 to 20/400), and 20/56 (range 20/20 to 20/400), respectively, (p>0.001, p=0.001 and p=0.05, respectively). At the 24-month follow-up, the improvement in VA, defined as a halving of the visual angle, occurred in 37.5% of the cases. CONCLUSIONS: Anti-VEGF monotherapy represents a useful treatment option for RAP, with stable or improved visual acuity in 62.5% of patients at 2 years. 25% of eyes required only a single injection, but in most cases (75%) repeated treatments were required, highlighting the need for long term follow-up. Although, in this small study, the results for visual improvement were not statistically significant beyond 3 months, our findings warrant further large-scale investigation.
AIM: To study the long-term visual and anatomical outcomes of antivascular endothelial growth factor (VEGF) monotherapy for the treatment of patients with retinal angiomatous proliferation (RAP). METHODS: Retrospective review of patients who were diagnosed as having AMD and RAP lesions, and who received anti-VEGF injections as the only mode of therapy. RESULTS: 20 eyes (15 patients; nine women, six men) with RAP lesions treated by anti-VEGF were encountered. The mean patient age was 85.8 years (SD+/-4.54). Nine eyes were treated with intravitreal ranibizumab alone, eight eyes were treated with bevacizumab alone, and three eyes received both drugs. At 1, 3 and 6 months' follow-up the median VA had improved from baseline (20/72) to 20/52 (range: 20/25 to 20/400), 20/45 (range 20/20 to 20/400), and 20/56 (range 20/20 to 20/400), respectively, (p>0.001, p=0.001 and p=0.05, respectively). At the 24-month follow-up, the improvement in VA, defined as a halving of the visual angle, occurred in 37.5% of the cases. CONCLUSIONS: Anti-VEGF monotherapy represents a useful treatment option for RAP, with stable or improved visual acuity in 62.5% of patients at 2 years. 25% of eyes required only a single injection, but in most cases (75%) repeated treatments were required, highlighting the need for long term follow-up. Although, in this small study, the results for visual improvement were not statistically significant beyond 3 months, our findings warrant further large-scale investigation.
Authors: L A Yannuzzi; S Negrão; T Iida; C Carvalho; H Rodriguez-Coleman; J Slakter; K B Freund; J Sorenson; D Orlock; N Borodoker Journal: Retina Date: 2001 Impact factor: 4.256
Authors: Philip J Rosenfeld; David M Brown; Jeffrey S Heier; David S Boyer; Peter K Kaiser; Carol Y Chung; Robert Y Kim Journal: N Engl J Med Date: 2006-10-05 Impact factor: 91.245
Authors: Richard F Spaide; Ketan Laud; Howard F Fine; James M Klancnik; Catherine B Meyerle; Lawrence A Yannuzzi; John Sorenson; Jason Slakter; Yale L Fisher; Michael J Cooney Journal: Retina Date: 2006-04 Impact factor: 4.256
Authors: Catherine B Meyerle; K Bailey Freund; Diana Iturralde; Richard F Spaide; John A Sorenson; Jason S Slakter; James M Klancnik; Yale L Fisher; Michael J Cooney; Lawrence A Yannuzzi Journal: Retina Date: 2007 Apr-May Impact factor: 4.256
Authors: Ebenezer Daniel; James Shaffer; Gui-shuang Ying; Juan E Grunwald; Daniel F Martin; Glenn J Jaffe; Maureen G Maguire Journal: Ophthalmology Date: 2015-12-08 Impact factor: 12.079
Authors: Eiichi Hasegawa; Harry Sweigard; Deeba Husain; Ana M Olivares; Bo Chang; Kaylee E Smith; Amy E Birsner; Robert J D'Amato; Norman A Michaud; Yinan Han; Demetrios G Vavvas; Joan W Miller; Neena B Haider; Kip M Connor Journal: PLoS One Date: 2014-09-04 Impact factor: 3.240